AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$ABEO

Alvino Mark sold $88K of ABEO

Alvino Mark sold 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.86 on 2026-09-01.

Original reporting
SEC EDGAR · Alvino Mark
Published Sep 1, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The disclosed sale provides fresh, primary information but its modest size limits trading relevance.

02

Market read

A routine insider sale with limited market impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this sale.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-01

Background

Form 4 filing from SEC EDGAR reporting a director's stock sale.

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

Director Alvino Mark sold 15,000 shares for $87,966, reducing his stake to 62,065 shares.

Expected impact

Minor short‑term dip or flat price action.

Evidence & confidence

The transaction size (~$88k) is small relative to market cap; insider sales of this magnitude rarely trigger large moves.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional effect.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

Even small insider sales can precede larger moves if the insider has private concerns.

Key entities

  • Company
    Abeona Therapeutics Inc.

    Biopharmaceutical company developing gene‑editing therapies.

  • Insider
    Alvino Mark

    Director of Abeona Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min